Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ismael Al-Ramahi is active.

Publication


Featured researches published by Ismael Al-Ramahi.


Journal of Biological Chemistry | 2006

CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation.

Ismael Al-Ramahi; Yung C. Lam; Hung Kai Chen; Beatrice De Gouyon; Minghang Zhang; Alma M. Perez; Joana Branco; Maria de Haro; Cam Patterson; Huda Y. Zoghbi; Juan Botas

CHIP (C terminus of Hsc-70 interacting protein) is an E3 ligase that links the protein folding machinery with the ubiquitin-proteasome system and has been implicated in disorders characterized by protein misfolding and aggregation. Here we investigate the role of CHIP in protecting from ataxin-1-induced neurodegeneration. Ataxin-1 is a polyglutamine protein whose expansion causes spinocerebellar ataxia type-1 (SCA1) and triggers the formation of nuclear inclusions (NIs). We find that CHIP and ataxin-1 proteins directly interact and co-localize in NIs both in cell culture and SCA1 postmortem neurons. CHIP promotes ubiquitination of expanded ataxin-1 both in vitro and in cell culture. The Hsp70 chaperone increases CHIP-mediated ubiquitination of ataxin-1 in vitro, and the tetratricopeptide repeat domain, which mediates CHIP interactions with chaperones, is required for ataxin-1 ubitiquination in cell culture. Interestingly, CHIP also interacts with and ubiquitinates unexpanded ataxin-1. Overexpression of CHIP in a Drosophila model of SCA1 decreases the protein steady-state levels of both expanded and unexpanded ataxin-1 and suppresses their toxicity. Finally we investigate the ability of CHIP to protect against toxicity caused by expanded polyglutamine tracts in different protein contexts. We find that CHIP is not effective in suppressing the toxicity caused by a bare 127Q tract with only a short hemaglutinin tag, but it is very efficient in suppressing toxicity caused by a 128Q tract in the context of an N-terminal huntingtin backbone. These data underscore the importance of the protein framework for modulating the effects of polyglutamine-induced neurodegeneration.


Neuron | 2012

Network Organization of the Huntingtin Proteomic Interactome in Mammalian Brain

Dyna I. Shirasaki; Erin R. Greiner; Ismael Al-Ramahi; Michelle Gray; Pinmanee Boontheung; Daniel H. Geschwind; Juan Botas; Giovanni Coppola; Steve Horvath; Joseph A. Loo; X. William Yang

We used affinity-purification mass spectrometry to identify 747 candidate proteins that are complexed with Huntingtin (Htt) in distinct brain regions and ages in Huntingtons disease (HD) and wild-type mouse brains. To gain a systems-level view of the Htt interactome, we applied Weighted Correlation Network Analysis to the entire proteomic data set to unveil a verifiable rank of Htt-correlated proteins and a network of Htt-interacting protein modules, with each module highlighting distinct aspects of Htt biology. Importantly, the Htt-containing module is highly enriched with proteins involved in 14-3-3 signaling, microtubule-based transport, and proteostasis. Top-ranked proteins in this module were validated as Htt interactors and genetic modifiers in an HD Drosophila model. Our study provides a compendium of spatiotemporal Htt-interacting proteins in the mammalian brain and presents an approach for analyzing proteomic interactome data sets to build in vivo protein networks in complex tissues, such as the brain.


Neuron | 2010

Matrix Metalloproteinases are Modifiers of Huntingtin Proteolysis and Toxicity in Huntington’s Disease

John P. Miller; Jennifer Holcomb; Ismael Al-Ramahi; Maria de Haro; Juliette Gafni; Ningzhe Zhang; Eugene Kim; Mario Sanhueza; Cameron Torcassi; Seung Kwak; Juan Botas; Robert E. Hughes

Proteolytic cleavage of huntingtin (Htt) is known to be a key event in the pathogenesis of Huntingtons disease (HD). Our understanding of proteolytic processing of Htt has thus far focused on the protease families-caspases and calpains. Identifying critical proteases involved in Htt proteolysis and toxicity using an unbiased approach has not been reported. To accomplish this, we designed a high-throughput western blot-based screen to examine the generation of the smallest N-terminal polyglutamine-containing Htt fragment. We screened 514 siRNAs targeting the repertoire of human protease genes. This screen identified 11 proteases that, when inhibited, reduced Htt fragment accumulation. Three of these belonged to the matrix metalloproteinase (MMP) family. One family member, MMP-10, directly cleaves Htt and prevents cell death when knocked down in striatal Hdh(111Q/111Q) cells. Correspondingly, MMPs are activated in HD mouse models, and loss of function of Drosophila homologs of MMPs suppresses Htt-induced neuronal dysfunction in vivo.


Nature Neuroscience | 2016

Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice

Peter Langfelder; Jeffrey P. Cantle; Doxa Chatzopoulou; Nan Wang; Fuying Gao; Ismael Al-Ramahi; Xiao-Hong Lu; Eliana Marisa Ramos; Karla Elzein; Yining Zhao; Sandeep Deverasetty; Andreas Tebbe; Christoph Schaab; Daniel J. Lavery; David Howland; Seung Kwak; Juan Botas; Jeffrey S. Aaronson; Jim Rosinski; Giovanni Coppola; Steve Horvath; X. William Yang

To gain insight into how mutant huntingtin (mHtt) CAG repeat length modifies Huntingtons disease (HD) pathogenesis, we profiled mRNA in over 600 brain and peripheral tissue samples from HD knock-in mice with increasing CAG repeat lengths. We found repeat length-dependent transcriptional signatures to be prominent in the striatum, less so in cortex, and minimal in the liver. Coexpression network analyses revealed 13 striatal and 5 cortical modules that correlated highly with CAG length and age, and that were preserved in HD models and sometimes in patients. Top striatal modules implicated mHtt CAG length and age in graded impairment in the expression of identity genes for striatal medium spiny neurons and in dysregulation of cyclic AMP signaling, cell death and protocadherin genes. We used proteomics to confirm 790 genes and 5 striatal modules with CAG length–dependent dysregulation at the protein level, and validated 22 striatal module genes as modifiers of mHtt toxicities in vivo.


Nature | 2013

RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1

Jeehye Park; Ismael Al-Ramahi; Qiumin Tan; Nissa Mollema; Javier R. Diaz-García; Tatiana Gallego-Flores; Hsiang Chih Lu; Sarita Lagalwar; Lisa A. Duvick; Hyojin Kang; Yoontae Lee; Paymaan Jafar-Nejad; Layal S. Sayegh; Ronald Richman; Xiuyun Liu; Yan Gao; Chad A. Shaw; J. Simon C. Arthur; Harry T. Orr; Thomas F. Westbrook; Juan Botas; Huda Y. Zoghbi

Many neurodegenerative disorders, such as Alzheimer’s, Parkinson’s and polyglutamine diseases, share a common pathogenic mechanism: the abnormal accumulation of disease-causing proteins, due to either the mutant protein’s resistance to degradation or overexpression of the wild-type protein. We have developed a strategy to identify therapeutic entry points for such neurodegenerative disorders by screening for genetic networks that influence the levels of disease-driving proteins. We applied this approach, which integrates parallel cell-based and Drosophila genetic screens, to spinocerebellar ataxia type 1 (SCA1), a disease caused by expansion of a polyglutamine tract in ataxin 1 (ATXN1). Our approach revealed that downregulation of several components of the RAS–MAPK–MSK1 pathway decreases ATXN1 levels and suppresses neurodegeneration in Drosophila and mice. Importantly, pharmacological inhibitors of components of this pathway also decrease ATXN1 levels, suggesting that these components represent new therapeutic targets in mitigating SCA1. Collectively, these data reveal new therapeutic entry points for SCA1 and provide a proof-of-principle for tackling other classes of intractable neurodegenerative diseases.


PLOS Genetics | 2005

dAtaxin-2 Mediates Expanded Ataxin-1-Induced Neurodegeneration in a Drosophila Model of SCA1

Ismael Al-Ramahi; Alma M. Perez; Janghoo Lim; Minghang Zhang; Rie D Sørensen; Maria de Haro; Joana Branco; Stefan M. Pulst; Huda Y. Zoghbi; Juan Botas

Spinocerebellar ataxias (SCAs) are a genetically heterogeneous group of neurodegenerative disorders sharing atrophy of the cerebellum as a common feature. SCA1 and SCA2 are two ataxias caused by expansion of polyglutamine tracts in Ataxin-1 (ATXN1) and Ataxin-2 (ATXN2), respectively, two proteins that are otherwise unrelated. Here, we use a Drosophila model of SCA1 to unveil molecular mechanisms linking Ataxin-1 with Ataxin-2 during SCA1 pathogenesis. We show that wild-type Drosophila Ataxin-2 (dAtx2) is a major genetic modifier of human expanded Ataxin-1 (Ataxin-1[82Q]) toxicity. Increased dAtx2 levels enhance, and more importantly, decreased dAtx2 levels suppress Ataxin-1[82Q]-induced neurodegeneration, thereby ruling out a pathogenic mechanism by depletion of dAtx2. Although Ataxin-2 is normally cytoplasmic and Ataxin-1 nuclear, we show that both dAtx2 and hAtaxin-2 physically interact with Ataxin-1. Furthermore, we show that expanded Ataxin-1 induces intranuclear accumulation of dAtx2/hAtaxin-2 in both Drosophila and SCA1 postmortem neurons. These observations suggest that nuclear accumulation of Ataxin-2 contributes to expanded Ataxin-1-induced toxicity. We tested this hypothesis engineering dAtx2 transgenes with nuclear localization signal (NLS) and nuclear export signal (NES). We find that NLS-dAtx2, but not NES-dAtx2, mimics the neurodegenerative phenotypes caused by Ataxin-1[82Q], including repression of the proneural factor Senseless. Altogether, these findings reveal a previously unknown functional link between neurodegenerative disorders with common clinical features but different etiology.


Nature Neuroscience | 2013

Identification of NUB1 as a suppressor of mutant Huntingtin toxicity via enhanced protein clearance

Boxun Lu; Ismael Al-Ramahi; Antonio Valencia; Qiong Wang; Frada Berenshteyn; Haidi Yang; Tatiana Gallego-Flores; Salah Ichcho; Arnaud Lacoste; Marc Hild; Marian DiFiglia; Juan Botas; James Palacino

Huntingtons disease is caused by expanded CAG repeats in HTT, conferring toxic gain of function on mutant HTT (mHTT) protein. Reducing mHTT amounts is postulated as a strategy for therapeutic intervention. We conducted genome-wide RNA interference screens for genes modifying mHTT abundance and identified 13 hits. We tested 10 in vivo in a Drosophila melanogaster Huntingtons disease model, and 6 exhibited activity consistent with the in vitro screening results. Among these, negative regulator of ubiquitin-like protein 1 (NUB1) overexpression lowered mHTT in neuronal models and rescued mHTT-induced death. NUB1 reduces mHTT amounts by enhancing polyubiquitination and proteasomal degradation of mHTT protein. The process requires CUL3 and the ubiquitin-like protein NEDD8 necessary for CUL3 activation. As a potential approach to modulating NUB1 for treatment, interferon-β lowered mHTT and rescued neuronal toxicity through induction of NUB1. Thus, we have identified genes modifying endogenous mHTT using high-throughput screening and demonstrate NUB1 as an exemplar entry point for therapeutic intervention of Huntingtons disease.


Science Translational Medicine | 2014

Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington’s disease

Xiao-Hong Lu; Virginia B. Mattis; Nan Wang; Ismael Al-Ramahi; Nick van den Berg; Silvina A. Fratantoni; Henry J. Waldvogel; Erin R. Greiner; Alexander P. Osmand; Karla Elzein; Jingbo Xiao; Sipke Dijkstra; Remko de Pril; Harry V. Vinters; Richard L.M. Faull; Ethan Signer; Seung Kwak; Juan J. Marugan; Juan Botas; David F. Fischer; Clive N. Svendsen; Ignacio Munoz-Sanjuan; X. William Yang

Reducing ATM signaling is neuroprotective in cell and animal models of Huntington’s disease. Cashing in with ATM Age-related neurodegenerative disorders, including Alzheimer’s disease and Huntington’s disease (HD), consistently show elevated markers of DNA damage. It remains unclear, however, whether such defects are mere consequences of or actively contribute to disease processes. In a new study, Lu et al. show that ataxia-telangiectasia mutated (ATM), a pivotal signaling molecule in the DNA damage response pathway, can modify the toxicity of the mutant protein that causes HD. ATM signaling activity was aberrantly increased in HD cells, animal models of HD, and postmortem brain tissue from HD patients. Reducing ATM signaling by genetic manipulation or using small-molecule inhibitors of ATM consistently reduced HD protein toxicities in cellular and animal models. Age-related neurodegenerative disorders including Alzheimer’s disease and Huntington’s disease (HD) consistently show elevated DNA damage, but the relevant molecular pathways in disease pathogenesis remain unclear. One attractive gene is that encoding the ataxia-telangiectasia mutated (ATM) protein, a kinase involved in the DNA damage response, apoptosis, and cellular homeostasis. Loss-of-function mutations in both alleles of ATM cause ataxia-telangiectasia in children, but heterozygous mutation carriers are disease-free. Persistently elevated ATM signaling has been demonstrated in Alzheimer’s disease and in mouse models of other neurodegenerative diseases. We show that ATM signaling was consistently elevated in cells derived from HD mice and in brain tissue from HD mice and patients. ATM knockdown protected from toxicities induced by mutant Huntingtin (mHTT) fragments in mammalian cells and in transgenic Drosophila models. By crossing the murine Atm heterozygous null allele onto BACHD mice expressing full-length human mHTT, we show that genetic reduction of Atm gene dosage by one copy ameliorated multiple behavioral deficits and partially improved neuropathology. Small-molecule ATM inhibitors reduced mHTT-induced death of rat striatal neurons and induced pluripotent stem cells derived from HD patients. Our study provides converging genetic and pharmacological evidence that reduction of ATM signaling could ameliorate mHTT toxicity in cellular and animal models of HD, suggesting that ATM may be a useful therapeutic target for HD.


The EMBO Journal | 2015

Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation

Marie‐Thérèse El‐Daher; Emilie Hangen; Julie Bruyère; Ghislaine Poizat; Ismael Al-Ramahi; Raúl Pardo; Nicolas Bourg; Sylvie Souquere; Céline Mayet; Gérard Pierron; Sandrine Lévêque-Fort; Juan Botas; Sandrine Humbert; Frédéric Saudou

Cleavage of mutant huntingtin (HTT) is an essential process in Huntingtons disease (HD), an inherited neurodegenerative disorder. Cleavage generates N‐ter fragments that contain the polyQ stretch and whose nuclear toxicity is well established. However, the functional defects induced by cleavage of full‐length HTT remain elusive. Moreover, the contribution of non‐polyQ C‐terminal fragments is unknown. Using time‐ and site‐specific control of full‐length HTT proteolysis, we show that specific cleavages are required to disrupt intramolecular interactions within HTT and to cause toxicity in cells and flies. Surprisingly, in addition to the canonical pathogenic N‐ter fragments, the C‐ter fragments generated, that do not contain the polyQ stretch, induced toxicity via dilation of the endoplasmic reticulum (ER) and increased ER stress. C‐ter HTT bound to dynamin 1 and subsequently impaired its activity at ER membranes. Our findings support a role for HTT on dynamin 1 function and ER homoeostasis. Proteolysis‐induced alteration of this function may be relevant to disease.


Cell and Tissue Research | 2010

Detailed analysis of leucokinin-expressing neurons and their candidate functions in the Drosophila nervous system

Maria de Haro; Ismael Al-Ramahi; Jonathan Benito-Sipos; Begoña López-Arias; Belén Dorado; Jan A. Veenstra; Pilar Herrero

The distribution of leucokinin (LK) neurons in the central nervous system (CNS) of Drosophila melanogaster was described by immunolabelling many years ago. However, no detailed underlying information of the input or output connections of their neurites was then available. Here, we provide a more accurate morphological description by employing a novel LK-specific GAL4 line that recapitulates LK expression. In order to analyse the possible afferent and efferent neural candidates of LK neurons, we used this lk-GAL4 line together with other CNS-Gal4 lines, combined with antisera against various neuropeptides or neurotransmitters. We found four kinds of LK neurons in the brain. (1) The lateral horn neurons connect the antennal glomerula to the mushroom bodies. (2) The suboesophageal neurons connect the gustatory receptors to the suboesophageal ganglia and ventral nerve cord. (3) The anterior neurons innervate the corpus cardiacum of the ring gland but LK expression is surprisingly not detectable from the third instar onwards in these neurons. (4) A set of abdominal ganglion neurons connect to the dorsal median tract in larvae and send their axons to a segmental muscle 8. Thus, the methods employed in our study can be used to identify individual neuropeptidergic neurons and thereby characterize functional cues or developmental transformations in their differentiation.

Collaboration


Dive into the Ismael Al-Ramahi's collaboration.

Top Co-Authors

Avatar

Juan Botas

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Maria de Haro

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Huda Y. Zoghbi

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Alma M. Perez

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Jeehye Park

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Joana Branco

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cristian A. Lasagna-Reeves

University of Texas Medical Branch

View shared research outputs
Researchain Logo
Decentralizing Knowledge